Literature DB >> 9688906

Melatonin improves cerebral circulation security margin in rats.

O Régrigny1, P Delagrange, E Scalbert, J Atkinson, I Lartaud-Idjouadiene.   

Abstract

Because melatonin is a cerebral vasoconstrictor agent, we tested whether it could shift the lower limit of cerebral blood flow autoregulation to a lower pressure level, by improving the cerebrovascular dilatory reserve, and thus widen the security margin. Cerebral blood flow and cerebrovascular resistance were measured by hydrogen clearance in the frontal cortex of adult male Wistar rats. The cerebrovasodilatory reserve was evaluated from the increase in the cerebral blood flow under hypercapnia. The lower limit of cerebral blood flow autoregulation was evaluated from the fall in cerebral blood flow following hypotensive hemorrhage. Rats received melatonin infusions of 60, 600, or 60,000 ng . kg-1 . h-1, a vehicle infusion, or no infusion (n = 9 rats per group). Melatonin induced concentration-dependent cerebral vasoconstriction (up to 25% of the value for cerebrovascular resistance of the vehicle group). The increase in vasoconstrictor tone was accompanied by an improvement in the vasodilatory response to hypercapnia (+50 to +100% vs. vehicle) and by a shift in the lower limit of cerebral blood flow autoregulation to a lower mean arterial blood pressure level (from 90 to 50 mmHg). Because melatonin had no effect on baseline mean arterial blood pressure, the decrease in the lower limit of cerebral blood flow autoregulation led to an improvement in the cerebrovascular security margin (from 17% in vehicle to 30, 55, and 55% in the low-, medium-, and high-dose melatonin groups, respectively). This improvement in the security margin suggests that melatonin could play an important role in the regulation of cerebral blood flow and may diminish the risk of hypoperfusion-induced cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688906     DOI: 10.1152/ajpheart.1998.275.1.H139

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization.

Authors:  Angélique Levoye; Julie Dam; Mohammed A Ayoub; Jean-Luc Guillaume; Cyril Couturier; Philippe Delagrange; Ralf Jockers
Journal:  EMBO J       Date:  2006-06-15       Impact factor: 11.598

2.  Effects of melatonin on rat pial arteriolar diameter in vivo.

Authors:  O Régrigny; P Delagrange; E Scalbert; I Lartaud-Idjouadiene; J Atkinson; J M Chillon
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 4.  Neuroprotective Mechanisms of Melatonin in Hemorrhagic Stroke.

Authors:  Hai-Jian Wu; Cheng Wu; Huan-Jiang Niu; Kun Wang; Lian-Jie Mo; An-Wen Shao; Brandon J Dixon; Jian-Min Zhang; Shu-Xu Yang; Yi-Rong Wang
Journal:  Cell Mol Neurobiol       Date:  2017-01-28       Impact factor: 5.046

5.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 6.  Melatonin for cognitive impairment.

Authors:  S L Jansen; D A Forbes; V Duncan; D G Morgan
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

7.  Melatonin.

Authors:  Paul Pévet
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

Review 8.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.